Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Clinical Significance of the IL-33-ACOD1-MARCO Axis in HBV-Related Acute-on-Chronic Liver Failure

15 de noviembre de 2026 actualizado por: Minghui Li

The IL-33-ACOD1-MARCO Axis in Ameliorating Immune-Mediated Liver Injury and Its Clinical Significance in HBV-Related Acute-on-Chronic Liver Failure

This single-center, prospective observational study will enroll 80 adults: 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-related acute-on-chronic liver failure (HBV-ACLF). The study will not assign any research treatment, and all participants will continue to receive routine clinical care. A 5 mL peripheral blood sample will be collected once from the first three groups. Participants with HBV-ACLF will have 5 mL blood collected at baseline, Day 28, and Day 90, and their 28-day and 90-day survival status will be recorded. Plasma IL-33, IL-6, TNF-alpha, and IL-10 will be measured. Peripheral blood CD14-positive monocytes will be isolated, and ACOD1 and MARCO mRNA expression will be measured by quantitative PCR. The study will compare these markers across groups and assess their relationships with inflammation, disease severity, longitudinal clinical changes, and short-term outcomes.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Descripción detallada

HBV-related acute-on-chronic liver failure is characterized by rapid clinical deterioration, systemic inflammation, and high short-term mortality. Previous experimental work in a mouse model of immune-mediated liver injury suggested that IL-33 may induce ACOD1 expression in hepatic macrophages and increase MARCO expression through an itaconate-related pathway, thereby enhancing efferocytosis and reducing inflammatory injury. The complete IL-33-ACOD1-MARCO axis has not been established in patients, and measurements in peripheral blood CD14-positive monocytes cannot be considered direct measurements of liver-resident macrophage function.

This study combines a cross-sectional comparison with longitudinal follow-up. At baseline, plasma IL-33 and inflammatory cytokines and CD14-positive monocyte ACOD1 and MARCO mRNA expression will be compared among healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-ACLF. In the HBV-ACLF group, associations with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, IL-6, TNF-alpha, and IL-10 will be evaluated. Participants with HBV-ACLF will undergo follow-up at Day 28 and Day 90 to assess biomarker changes, all-cause mortality, and liver transplantation status.

Blood will be collected in EDTA-K2 tubes and processed within 2 hours. Plasma IL-33 will be measured by ELISA, and IL-6, TNF-alpha, and IL-10 will be measured by Luminex. Peripheral blood mononuclear cells will be isolated by Ficoll density-gradient centrifugation, followed by CD14-positive magnetic-bead selection and flow-cytometric verification of purity. ACOD1 and MARCO mRNA expression will be measured by quantitative PCR using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Tipo de estudio

De observación

Inscripción (Estimado)

80

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100015
        • : Beijing Ditan Hospital, Capital Medical University
        • Contacto:
          • Minghui Li, master
          • Número de teléfono: 8613693259096
          • Correo electrónico: wuhm2000@sina.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

N/A

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adults aged 18 to 70 years will be recruited at Beijing Ditan Hospital, Capital Medical University. The study population will include healthy individuals undergoing routine health examinations and patients receiving care at the Liver Disease Center for chronic hepatitis B, HBV-related cirrhosis, or HBV-related acute-on-chronic liver failure. Individuals who meet the applicable group definition and the inclusion and exclusion criteria will be enrolled after providing written informed consent. The planned enrollment is 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-ACLF.

Descripción

Inclusion Criteria:

  • Aged 18 to 70 years, regardless of sex.
  • Meets the criteria for one of the following study groups:

Healthy Control Group: No history of liver disease, negative hepatitis B surface antigen (HBsAg), and normal liver function.

Chronic Hepatitis B Group: HBsAg positivity for more than 6 months, no imaging evidence of cirrhosis, and does not meet the diagnostic criteria for HBV-related acute-on-chronic liver failure (HBV-ACLF).

HBV-Related Cirrhosis Group: HBsAg positivity for more than 6 months and cirrhosis confirmed by imaging or pathological examination, without meeting the diagnostic criteria for HBV-ACLF.

HBV-ACLF Group: HBsAg positivity for more than 6 months and meets the COSSH-ACLF diagnostic criteria.

-Fully understands the study and voluntarily provides written informed consent.

Exclusion Criteria:

  • Coinfection with hepatitis A, C, D, or E virus, or the presence of another liver disease, including autoimmune liver disease, drug-induced liver injury, or alcohol-related liver disease.
  • Confirmed hepatocellular carcinoma.
  • Pregnancy or breastfeeding.
  • Treatment with immunosuppressive agents or high-dose glucocorticoids within 4 weeks before enrollment.
  • Human immunodeficiency virus infection.
  • Severe renal impairment, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m².
  • Incomplete key clinical data at enrollment or an anticipated inability to complete the study sampling and follow-up required for the assigned group.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Healthy Control

Adults without a history of liver disease, with negative hepatitis B surface antigen and normal liver function. Participants will undergo one study blood collection at enrollment.

Chronic Hepatitis B

Adults with hepatitis B surface antigen positivity for more than 6 months, without imaging evidence of cirrhosis and not meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Cirrhosis

Adults with chronic HBV infection and cirrhosis confirmed by imaging or pathology, without meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Acute-on-Chronic Liver Failure

Adults with hepatitis B surface antigen positivity for more than 6 months who meet the COSSH-ACLF diagnostic criteria. Participants will undergo study blood collection at baseline, Day 28, and Day 90 and will be followed for 28-day and 90-day survival outcomes.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Plasma IL-33 Concentration at Baseline Across Study Groups
Periodo de tiempo: Baseline (at enrollment or hospital admission)

Plasma IL-33 concentration will be measured in EDTA plasma by enzyme-linked immunosorbent assay (ELISA) in healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-related acute-on-chronic liver failure.

Baseline (at enrollment or hospital admission)
ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Periodo de tiempo: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. ACOD1 mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)
MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Periodo de tiempo: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. MARCO mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlation of Plasma IL-33 With ACOD1 and MARCO mRNA Expression in Participants With HBV-ACLF
Periodo de tiempo: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, Spearman correlation coefficients will be calculated between plasma IL-33 concentration and ACOD1 and MARCO mRNA relative expression in peripheral blood CD14-positive monocytes.

Baseline
Association of ACOD1 and MARCO mRNA Expression With Disease Severity and Inflammatory Markers in Participants With HBV-ACLF
Periodo de tiempo: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, correlations of ACOD1 and MARCO mRNA relative expression with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, plasma IL-6, TNF-alpha, and IL-10 will be assessed.

Baseline
28-Day All-Cause Mortality in Participants With HBV-ACLF
Periodo de tiempo: From baseline through Day 28

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 28
90-Day All-Cause Mortality in Participants With HBV-ACLF
Periodo de tiempo: From baseline through Day 90

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 90
Change in Plasma IL-33 Concentration in Participants With HBV-ACLF
Periodo de tiempo: Baseline, Day 28, and Day 90

Plasma IL-33 concentration will be measured by ELISA at baseline, Day 28, and Day 90. Within-participant changes over time will be described and analyzed using repeated-measures methods specified in the protocol.

Baseline, Day 28, and Day 90
Change in ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Periodo de tiempo: Baseline, Day 28, and Day 90

ACOD1 mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90
Change in MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Periodo de tiempo: Baseline, Day 28, and Day 90

MARCO mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

30 de noviembre de 2026

Finalización primaria (Estimado)

31 de mayo de 2027

Finalización del estudio (Estimado)

31 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

15 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

15 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ZZLX2026052

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .